Associate Professor of Urology, University Tex Houston
Urology
Dr. Louis L. Pisters, MD
|
|
Give Review
Louis L. Pisters, MD practices Urology. He received 5 awards: "America's Top Doctors", "Top Doctors:SE Texas", "America's Top Doctors for Cancer", "Fellow (FACS)" and "Super Doctor". Louis Pisters is a published doctor as well. He has 100 publications published. The latest was: Neoadjuvant Systemic Therapy Before Radical Prostatectomy in High-Risk Prostate Cancer Does Not Increase Surgical Morbidity: Contemporary Results Using the Clavien Sys... He is registered with Medicare.
Publications
- Outcome of patients with clinically node-positive Bladder cancer undergoing consolidative surgery after preoperative chemotherapy: The M.D. Anderson Cancer Center Expe...
- Neoadjuvant Systemic Therapy Before Radical Prostatectomy in High-Risk Prostate Cancer Does Not Increase Surgical Morbidity: Contemporary Results Using the Clavien Sys...
- Posttraumatic stress and depressive symptoms in Renal cell carcinoma: association with quality of life and utility of single-item distress screening.
- Robotic or open radical Prostatectomy after previous open surgery in the pelvic region.
- Clinically nonmetastatic Renal cell carcinoma with sarcomatoid dedifferentiation: Natural history and outcomes after surgical resection with curative intent.
- Clinical Outcomes in cT1 Micropapillary Bladder Cancer.
- Impact of a clinical trial initiative on clinical trial enrollment in a multidisciplinary prostate Cancer clinic.
- Psychological states, serum markers and survival: associations and predictors of survival in patients with Renal cell carcinoma.
- Randomized controlled trial of expressive writing for patients with Renal cell carcinoma.
- Positive FDG-PET/CT Scans of a Residual Seminoma After Chemotherapy and Radiotherapy: Case Report and Review of the Literature.
- PCAT-1, a long noncoding RNA, regulates BRCA2 and controls homologous recombination in Cancer.
- Satisfaction with Information Used to Choose Prostate Cancer Treatment.
- Outcomes of salvage Prostate cryotherapy stratified by pre-treatment PSA: update from the COLD registry.
- Considerations for patient selection for focal therapy.
- Phase 1 prospective evaluation of the oncological adequacy of robotic assisted video-endoscopic inguinal lymphadenectomy in patients with Penile carcinoma.
- Predictors of biochemical failure in patients undergoing Prostate whole-gland salvage cryotherapy: a novel risk stratification model.
- Depressive symptoms and cortisol rhythmicity predict survival in patients with Renal cell carcinoma: role of inflammatory signaling.
- Integrated Hedgehog signaling is induced following castration in human and murine prostate Cancers.
- Comprehensive Assessment of Quality of Life and Psychosocial Adjustment in Patients With Renal Tumors Undergoing Open, Laparoscopic and Nephron Sparing Surgery.
- Prediction of erectile function following treatment for prostate Cancer.
- Persistent, Biologically Meaningful Prostate Cancer After 1 Year of Androgen Ablation and Docetaxel Treatment.
- Surgical management of lymph-node-positive prostate Cancer: improves symptomatic control.
- Recurrent seminomas: Clinical features and biologic implications.
- Cryotherapy for prostate Cancer: ready for prime time?
- Testis Cancer survivors' health behaviors: comparison with age-matched relative and demographically matched population controls.
- Modified suprapubic Prostatectomy without irrigation is safe.
- Port-site hernias occurring after the use of bladeless radially expanding trocars.
- Long-term outcomes and patient satisfaction of continent catheterizable limb and augmentation cystoplasty simultaneous with salvage Prostatectomy.
- Primary cryoablation nadir Prostate specific antigen and biochemical failure.
- Locally recurrent prostate Cancer after initial radiation therapy: a comparison of salvage radical prostatectomy versus cryotherapy.
- Ductal adenocarcinoma of the Prostate: clinical features and implications after local therapy.
- The effects of a presurgical stress management intervention for men with prostate Cancer undergoing radical prostatectomy.
- Long-term outcome for men with teratoma found at postchemotherapy retroperitoneal lymph node dissection.
- Selenium and vitamin E: cell type- and intervention-specific tissue effects in prostate Cancer.
- Pretreatment semen parameters in men with Cancer.
- Neoadjuvant platelet derived growth factor receptor inhibitor therapy combined with docetaxel and androgen ablation for high risk localized prostate Cancer.
- Outcome of patients with Bladder cancer with pN+ disease after preoperative chemotherapy and radical cystectomy.
- Salvage therapy for radiorecurrent prostate Cancer.
- Malignant transformation of Testicular teratoma: a chemoresistant phenotype.
- Salvage Prostate cryoablation: initial results from the cryo on-line data registry.
- Whole gland primary Prostate cryoablation: initial results from the cryo on-line data registry.
- Quality of life and satisfaction with outcome among prostate-Cancer survivors.
- Treatment failure after primary and salvage therapy for prostate Cancer.
- Can digital rectal examination or transrectal ultrasonography biopsy findings predict the side of nodal metastasis in prostate Cancer?
- Salvage surgery for locally recurrent prostate Cancer after radiation therapy: tricks of the trade.
- Phase III prevention trial of fenretinide in patients with resected non-muscle-invasive Bladder cancer.
- Viable germ cell tumor at postchemotherapy retroperitoneal lymph node dissection: can we predict patients at risk of Disease progression?
- Recurrence in nonseminomatous germ cell testis tumor patients with no viable tumor at postchemotherapy retroperitoneal lymph node dissection.
- Magnetic resonance imaging assessment of a convective therapy delivery paradigm in a canine Prostate model.
- An in vivo orthotopic canine model to evaluate distribution of intraprostatic injectate: implications for gene therapy and drug delivery for prostate Cancer.
- Organ preservation for muscle-invasive Bladder cancer by transurethral resection.
- Micropapillary Bladder cancer: a review of the University of Texas M. D. Anderson Cancer Center experience with 100 consecutive patients.
- Salvage prostatectomy with Bladder neck closure, continent catheterizable stoma and Bladder augmentation: feasibility and patient reported continence outcomes at 32 mo...
- An assessment of quality of life following radical Prostatectomy, high dose external beam radiation therapy and brachytherapy iodine implantation as monotherapies for ...
- Surgical management of growing teratoma syndrome: the M. D. Anderson Cancer center experience.
- Initial modulation of the tumor microenvironment accounts for thalidomide activity in prostate Cancer.
- Prostate Cancer progression in the presence of undetectable or low serum prostate-specific antigen level.
- Neoadjuvant therapy before radical Prostatectomy: where have we been? Where are we going?
- Recurrence pattern and proposed surveillance protocol following post-chemotherapy retroperitoneal lymph node dissection.
- Predictors of outcome in patients undergoing postchemotherapy retroperitoneal lymph node dissection for testicular Cancer.
- Viable malignant germ cell tumor in the postchemotherapy retroperitoneal lymph node dissection specimen: can it be predicted using clinical parameters?
- Chylous ascites after post-chemotherapy retroperitoneal lymph node dissection: review of the M. D. Anderson experience.
- Influence of obesity on biochemical and clinical failure after external-beam radiotherapy for localized prostate Cancer.
- Presalvage Prostate-specific antigen (PSA) and PSA doubling time as predictors of biochemical failure of salvage cryotherapy in patients with locally recurrent prostat...
- Impact of fellowship training on pathologic outcomes and complication rates of radical Prostatectomy.
- Surgery for locally advanced Disease.
- Biochemical disease-free survival in men younger than 60 years with prostate Cancer treated with radical prostatectomy.
- Selenium accumulation in Prostate tissue during a randomized, controlled short-term trial of l-selenomethionine: a Southwest Oncology Group Study.
- The case for early cystectomy in the treatment of nonmuscle invasive micropapillary Bladder carcinoma.
- Cystoprostatectomy for effective palliation of symptomatic Bladder invasion by prostate cancer.
- Is patient age a factor in the occurrence of prostate-specific antigen bounce phenomenon after external beam radiotherapy for prostate Cancer?
- Changes in serum proteomic patterns by presurgical alpha-tocopherol and L-selenomethionine supplementation in prostate Cancer.
- Symptomatic local recurrence of Prostate carcinoma after radiation therapy.
- Percutaneous radiofrequency ablation of Renal tumors: technique, complications, and outcomes.
- Metastatic penile Cancer in a young Caucasian male: impact of delayed diagnosis.
- Salvage surgery for bulky local recurrence of prostate Cancer following radical prostatectomy.
- Transrectal ultrasound versus magnetic resonance imaging for detection of rectal wall invasion by prostate Cancer.
- Evidence supporting preoperative chemotherapy for small cell carcinoma of the Bladder: a retrospective review of the M. D. Anderson cancer experience.
- Racial influence on biochemical disease-free survival in men treated with external-beam radiotherapy for localized prostate Cancer.
- Rise in serum PSA of 1.5 ng/mL above 24-month nadir after external beam radiotherapy is predictive of biochemical failure.
- Evidence that transfer of functional p53 protein results in increased apoptosis in prostate Cancer.
- Is there a role for surgery in the management of metastatic urothelial Cancer? The M. D. Anderson experience.
- Prognostic value of body mass index in patients undergoing nephrectomy for localized Renal tumors.
- Total pelvic exenteration: effective palliation of perineal pain in patients with locally recurrent prostate Cancer.
- Clinical features and treatment outcome of Hispanic men with prostate Cancer following external beam radiotherapy.
- Surgical management of Renal cell carcinoma associated with complex inferior vena caval thrombi.
- Is there a therapeutic role for post-chemotherapy retroperitoneal lymph node dissection in metastatic transitional cell carcinoma of the Bladder?
- Incomplete glandular ablation after salvage cryotherapy for recurrent prostate Cancer after radiotherapy.
- Bcl-2 is significantly overexpressed in localized radio-recurrent Prostate carcinoma, compared with localized radio-naive Prostate carcinoma.
- Repeat retroperitoneal lymph node dissection for metastatic testis Cancer.
- Multimodality management of urachal carcinoma: the M. D. Anderson Cancer Center experience.
- Salvage radical Prostatectomy: refinement of an effective procedure.
- Prostate specific antigen bounce phenomenon after external beam radiation for clinically localized prostate Cancer.
- Biochemical disease-free survival in men younger than 60 years with prostate Cancer treated with external beam radiation.
- Biological significance of c-met over expression in papillary Renal cell carcinoma.
- Salvage cryotherapy for recurrent prostate Cancer after radiotherapy: variables affecting patient outcome.
- Prostate carcinoma with testicular or penile metastases. Clinical, pathologic, and immunohistochemical features.
- Early nasogastric tube removal combined with metoclopramide after postchemotherapy retroperitoneal lymph node dissection for metastatic Testicular nonseminomatous germ...
- The association of p21((WAF-1/CIP1)) with progression to androgen-independent prostate Cancer.
Procedures Preformed
- AdRenalectomy
- Cystectomy
- Cystometry
- Cystotomy
- View All
Conditions Treated
- Bladder Cancer
- Bladder Infection
- Bladder Stones
- Blood in Urine (Hematuria)
- View All
Doctors Specialties
- Urology
Accepted Insurances
Awards
- America's Top Doctors
- Top Doctors:SE Texas
- America's Top Doctors for Cancer
- Fellow (FACS)
- Super Doctor
Education
-
University of Texas MD Anderson Cancer Center -
University of Florida -
University of Western Ontario
Hospital
-
University of Texas M.D. Anderson Cancer Center
Drug Facts
| NPI NUMBER | 1346285723 | |
| NPPES Provider LastName | PISTERS | |
| NPPES Provider FirstName | LOUIS | |
| NPPES Provider ZIPCode | 770304009 | |
| NPPES Provider State | TX | |
| Specialty Description | Urology | |
| Total Claim Count | 144.0 | |
| Distinct Opioid Count | 1.0 | |
| Opioid Claim Count | 19.0 | |
| Percent Opioid Claims | 13.19 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1346285723 |
| Last Name Of The Provider | PISTERS |
| First Name Of The Provider | LOUIS |
| View All |
Similar Doctors
|
|
Dr. John F. Ward III, MD
 This Doctor is OpenDoctor Recommended.
|
|
Dr. Richard Kim, MD |
|
|
Dr. David A. Swanson, MD |
|
|
Dr. John P. Laneri Jr., MD |
|
|
Dr. John S. Colen, MD |
|
|
Dr. Adam B. Hollander, MD |
|
|
Dr. Eugene K. Lee, MD |